Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WEL-PCOD
- Development stage
- Unknown
- Lead developer
- Adorshea Bioceutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
WEL-PCOD is a nutraceutical combination product developed by Adorshea Bioceutics for the management of Polycystic Ovary Syndrome (PCOS). The formulation typically consists of myo-inositol, d-chiro-inositol, levomefolic acid (L-methylfolate), and cholecalciferol (Vitamin D3). It is designed to address the metabolic and hormonal imbalances characteristic of PCOS by improving insulin sensitivity and restoring ovulatory function. Myo-inositol and d-chiro-inositol act as insulin sensitizers, facilitating glucose uptake and reducing hyperinsulinemia, which is a key driver of androgen excess in PCOS. Levomefolic acid provides the bioactive form of folate to support reproductive health, while cholecalciferol helps regulate calcium metabolism and hormonal pathways. WEL-PCOD is marketed in India as an approved supplement for women with PCOS.
- Brand names
- WEL-PCOD
02
Targets
FOLR1 (FRα)INSR (Insulin receptor)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on WEL-PCOD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WEL-PCOD.